Go back

Biosimilars Development Strategies(1st Edition)

Authors:

Sarfaraz K Niazi

Free biosimilars development strategies 1st edition sarfaraz k niazi 1032517018, 978-1032517018
9 ratings
Cover Type:Hardcover
Condition:Used

In Stock

Shipment time

Expected shipping within 2 Days
Access to 10 Million+ solutions Free
Ask 10 Questions from expert 200,000+ Expert answers
7 days-trial

Total Price:

$0

List Price: $140.00 Savings: $140(100%)

Book details

ISBN: 1032517018, 978-1032517018

Book publisher: CRC Press

Get your hands on the best-selling book Biosimilars Development Strategies 1st Edition for free. Feed your curiosity and let your imagination soar with the best stories coming out to you without hefty price tags. Browse SolutionInn to discover a treasure trove of fiction and non-fiction books where every page leads the reader to an undiscovered world. Start your literary adventure right away and also enjoy free shipping of these complimentary books to your door.

Book Summary: After 18 Years Since The First Biosimilar Was Approved, A Lot Has Changed, From The Regulatory Guidelines To The Stakeholder Perceptions About The Safety And Efficacy Of Biosimilars. However, The Development Costs Remain High, Preventing Faster Entry Into Markets With More Than 200 Choices. Analyzing The Regulatory Filings Of All Approved Biosimilars In The US And EU, A Deep Analysis Of The Scientific Principles, And Continuous Challenges To The Regulatory Authorities Have Made It Possible To Plan The Development On A Fast Track. This Book Teaches How To Cut The Current Time And Cost By More Than 70%, Based On The Author's Hands-on Experience.Features:Describes The Emergence Of Biosimilars Since The First Publication Of The Recombinant Engineering Patent, As Well As A Listing Of All Approved Recombinant Products, Their Patent Expiry And Their Adoption Across The Globe. Provides A Better Understanding Of The Safety And Efficacy Of Approved Biosimilars. Global Approval Requires Accommodating Guidelines And Detailed Planning To Avoid Redundancy As Well As High Costs. The Basic Expectations Of The Agencies Are Presented Here. Presents A Detailed Analysis Of All EU And FDA-approved Products With A Comparative Analysis. Renowned Author And Entrepreneur In The Field Of Drug Discovery And Production.